Our Technologies


Our stem cell expansion and screening technologies have enabled us to generate quality-assured stem cell lines in quantities sufficient to treat many hundreds of thousands of potential patients. Read More ....


Subscribe here for our Press Releases

Our Products


We have developed stem cell therapies for serious conditions such as stroke disability where the patient populations are significant and where few if any alternative treatments exist. Read More ....

Share Price

To view detailed share price information
for ReNeuron Group plc. Click Here

Latest News

Michael Hunt CFO of ReNeuron gives an interview at Edison to discuss company prospects More
Edison initiates coverage of ReNeuron with 7p per share (£125m) current valuation, ahead of key value inflection points across its therapeutic
Guildford, UK, 8 September 2014: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, announces the appointment of Olav Hellebø, a highly experienced pharmaceutical executive, as the Company’s new

ReNeuron is a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. Read more ....

©ReNeuron Group plc 2005-2014 All rights reserved

Privacy                Disclaimer